Association of antipsychotic polypharmacy with health service cost: a register-based cost analysis
- 31 March 2011
- journal article
- Published by Springer Nature in The European Journal of Health Economics
- Vol. 13 (3) , 355-363
Abstract
To investigate the association of antipsychotic polypharmacy in schizophrenia with cost of primary and secondary health service use. Comparative analysis of health service cost for patients prescribed antipsychotic polypharmacy versus antipsychotic monotherapy. Resource utilisation and costs were described using central Danish registers for a 2 year period (2007–2008). We included patients attached to one of two Danish psychiatric referral centres in 1 January 2008 and/or 1 January 2009. Their prescribed treatment with either antipsychotic polypharmacy or monotherapy at the two cross-sectional dates was recorded and used as proxy of polypharmacy exposure during the preceding year. A multivariate generalised linear model was fitted with total costs of primary and secondary health service use as dependent variable, and antipsychotic polypharmacy, diagnosis, age, gender, disease duration, psychiatric inpatient admissions, and treatment site as covariates. The sample consisted of 736 outpatients with a diagnosis in the schizophrenia spectrum. Antipsychotic polypharmacy was associated with significantly higher total health service costs compared with monotherapy (2007: 25% higher costs; 2008: 17% higher costs) when adjusting for potential confounders and risk factors. A subgroup analysis suggested that the excessive costs associated with antipsychotic polypharmacy were partly accounted for by the functional level of the patients. The results demonstrate that antipsychotic co-prescribing is associated with increased use of health care services, even though no causal relations can be inferred from an observational study.Keywords
This publication has 35 references indexed in Scilit:
- Augmentation of clozapine with a second antipsychotic – a meta‐analysis of randomized, placebo‐controlled studiesActa Psychiatrica Scandinavica, 2009
- Does the Addition of a Second Antipsychotic Drug Improve Clozapine Treatment?Schizophrenia Bulletin, 2008
- Antipsychotic Combinations vs Monotherapy in Schizophrenia: A Meta-analysis of Randomized Controlled TrialsSchizophrenia Bulletin, 2008
- Cost of antipsychotic polypharmacy in the treatment of schizophreniaBMC Psychiatry, 2008
- Addition of antipsychotics to medication regimens during schizophrenic inpatient carePsychiatry and Clinical Neurosciences, 2008
- Benefits and Risks of Antipsychotic PolypharmacyDrug Safety, 2008
- Simultaneous prescribing of atypical antipsychotics, conventional antipsychotics and anticholinergics—a European studyPharmacy World & Science, 2007
- High-Cost Use of Second-Generation Antipsychotics Under California's Medicaid ProgramPsychiatric Services, 2006
- Cost of schizophrenia studies: a methodological reviewHEPAC Health Economics in Prevention and Care, 2000
- Role of Antipsychotic Polypharmacotherapy in the Treatment of SchizophreniaCNS Drugs, 1999